MarketPulse

FDA warning letter

24 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Robbins Llp

ImmunityBio Stock Plummets 21% After FDA Warning Over Anktiva Cancer Claims

ImmunityBio faces securities fraud lawsuit after FDA warning letter alleges false Anktiva promotional claims. Stock dropped 21% to $7.42.
IBRXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Glancy Prongay Wolke & Rotter Llp

ImmunityBio Faces Securities Fraud Suit Over FDA Warning on Cancer Drug Claims

ImmunityBio faces securities fraud lawsuit after FDA warning over misleading cancer drug claims by Executive Chairman Soon-Shiong, triggering 21.12% stock decline.
IBRXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

ImmunityBio Stock Crashes 21% Following FDA Warning on Cancer Therapy

ImmunityBio faces securities fraud lawsuit after FDA warning letter on Anktiva cancer therapy. Stock plummeted to $7.42. Class action period open through May 26.
IBRXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

ImmunityBio Plummets 21% After FDA Warning Letter Over Misleading Cancer Drug Claims

ImmunityBio faces securities lawsuit after FDA warning letter over misleading Anktiva efficacy claims. Stock plunged 21%, erasing $2 billion in market value.
IBRXsecurities class actionstock price decline
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

ImmunityBio Plummets 21% After FDA Flags Cancer Drug Misleading Claims

ImmunityBio shares plunge 21% after FDA flags misleading cancer drug claims; $2B market cap erased. Securities lawsuit filed.
IBRXstock declinesecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Glancy Prongay Wolke & Rotter Llp

ImmunityBio Hit With Securities Fraud Suit Over Cancer Cure Claims

ImmunityBio faces class action lawsuit after FDA warning letter over false cancer claims by Executive Chairman Patrick Soon-Shiong. Stock plunged 21%.
IBRXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

ImmunityBio Stock Plummets 21% After FDA Warning on Cancer Drug Claims

ImmunityBio faces securities fraud lawsuit following FDA warning letter about misleading Anktiva advertisements. Stock dropped to $7.42 per share.
IBRXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

ImmunityBio Faces Class Action Over FDA Warning on Cancer Drug Claims

ImmunityBio (IBRX) shares plunged 21% after FDA warning letter citing misleading efficacy claims about immunotherapy drug Anktiva. Class action lawsuit underway with May 26 deadline.
IBRXinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Kessler Topaz Meltzer & Check, Llp

ImmunityBio Hit With Securities Fraud Suit Over Cancer Drug Claims

ImmunityBio faces class action lawsuit alleging false Anktiva claims. Stock plummeted 21% after FDA warning letter. Lead plaintiff deadline May 26, 2026.
IBRXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Robbins Geller Rudman & Dowd Llp

ImmunityBio Faces Securities Class Action Over Anktiva's False FDA Claims

ImmunityBio faces securities lawsuit over allegedly misleading Anktiva promotional materials. Stock fell 21% after FDA warning letter; investors can seek lead plaintiff status.
IBRXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

ImmunityBio Plummets 21% After FDA Flags Cancer Drug Misleading Claims

ImmunityBio faces securities lawsuit after FDA warning over misleading Anktiva cancer claims. Stock drops 21%, erasing $2B market cap.
IBRXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

ImmunityBio Faces Securities Fraud Class Action After FDA Warning, Stock Crashes 21%

ImmunityBio faces securities fraud lawsuit after FDA warns of false cancer cure claims for Anktiva, stock crashes 21% to $7.42.
IBRXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Levi & Korsinsky, Llp

ImmunityBio Hit With Securities Fraud Lawsuit Over Alleged Cancer Drug Misrepresentation

ImmunityBio faces securities fraud lawsuit after executive allegedly misrepresented ANKTIVA cancer drug capabilities; stock fell 21% following FDA Warning Letter.
IBRXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

ImmunityBio Stock Plunges 21% After FDA Warning on Cancer Drug Claims

ImmunityBio faces securities fraud lawsuit following FDA warning letter about misleading Anktiva advertisements. Stock fell to $7.42; investors have until May 26 to file claims.
IBRXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Kessler Topaz Meltzer & Check, Llp

ImmunityBio Faces Securities Fraud Suit Over Anktiva Cancer Claims

ImmunityBio faces securities fraud lawsuit after FDA warning over false Anktiva claims. Stock plunged 21%. Investor deadline May 26, 2026.
IBRXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

ImmunityBio Faces Major Securities Lawsuit Over FDA Warning on Drug Claims

ImmunityBio faces securities lawsuit after FDA warning letter regarding misleading efficacy claims for immunotherapy drug Anktiva, triggering 21% stock plunge.
IBRXinvestor lossessecurities class action
BenzingaBenzinga··Vandana Singh

FDA Issues Warning Letter to Medline Over Critical Quality System Failures at NY Facility

FDA flags Medline for quality lapses at New York facility producing angiographic syringes, citing manufacturing deficiencies and inadequate response to 221 complaints.
MDLNproduct recallmanufacturing deficiencies
GlobeNewswire Inc.GlobeNewswire Inc.··Kahn Swick & Foti, Llc

ImmunityBio Faces Securities Fraud Suit After FDA Warning Triggers 21% Stock Plunge

ImmunityBio hit with securities fraud class action following FDA warning letter over misleading Anktiva cancer therapy ads. Stock fell 21% to $7.42.
IBRXsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Kirby Mcinerney Llp

ImmunityBio Faces Securities Fraud Lawsuit Over Anktivas Marketing Claims

Kirby McInerney LLP filed securities fraud lawsuit against ImmunityBio over allegedly misleading Anktivas marketing. FDA warning letter triggered 21.2% stock decline.
KDIBRXSMCIsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

IBRX Stock Crashes 21% After FDA Warning on Unsupported Cancer Claims

ImmunityBio faces securities lawsuit after FDA warns of misleading Anktiva efficacy claims. Stock plunges 21%, erasing $2B in market value.
IBRXstock declinesecurities class action